Tony Hitchcock | 06/03/2015
Having worked in the development and production of early stage therapeutics for over 30 years I appreciate as much as anyone that this is often a highly challenging environment, not least with regards to overcoming technical and regulatory hurdles as well as seeking to meet a highly demanding timeline.
The development of new therapeutic entities is a complex and highly demanding enterprise to undertake; especially true for small biotech companies. Such projects are multi-faceted and include m...
To continue reading this story Click Here
RECOMMENDED
MSD announces Phase III data on investigational treatment to lower LDL Cholesterol (LDL-C)
2025-11-17
AI for Pharma & Healthcare 2025
2025-06-18
Upcoming Events
Pharma Contract Manufacturing
23 - 25 March 2026
Mercure Hotel MOA Berlin, Germany
Register Now |
View Agenda |
Learn More